Journal of Affective Disorders
January 26, 2024
Ludwig Honk, Cecilia U.D. Stenfors, Simon B. Goldberg et al.
41 citations
Using data from nearly 10,000 adults in the US and UK, psychedelic use over a two-month period was not linked to changes in psychotic symptoms overall. However, among people with a personal or family history of bipolar disorder, psychedelic use was associated with an increase in symptoms. Conversely, those with a personal history of psychotic disorders experienced a decrease in symptoms. These findings suggest that the effects of psychedelics on psychotic symptoms depend on an individual's psychiatric history.
Neuropharmacology
May 13, 2022
Cynthia E. Ortiz, Haley Maria Dourron, Noah W Sweat et al.
26 citations
Psilocybin-facilitated psychotherapy may be effective across many mental health conditions, but vulnerable populations, who carry a disproportionate mental health burden, have been largely excluded from clinical research. This report highlights the need to include these groups in studies, considering their problematic historical context and differential experiences with psychedelics. It offers actionable recommendations for future research, such as improved recruitment strategies, careful communication of subjective effects, building therapeutic alliance, multicultural competence, and flexible study designs. The authors call for expanded and improved research in this rapidly advancing field.
Psychopharmacology
December 11, 2023
Haley Maria Dourron, Charles D Nichols, Otto Simonsson et al.
23 citations
5-MeO-DMT, a tryptamine being developed as an antidepressant, may work through a mechanism distinct from typical psychedelics. This review compares the acute and post-acute effects of 5-MeO-DMT to epileptiform activity, particularly in temporal lobe epileptogenic zones. The authors note that 5-MeO-DMT has notable 5-HT1A receptor agonist properties and that aberrant 5-HT1A receptor functioning occurs in epilepsy. They suggest that 5-MeO-DMT's therapeutic mechanism might be partly mediated by evoking temporary epileptiform activity, similar to electroconvulsive therapy. The phenomenon of 'reactivations'—sudden re-experiencing of drug effects common after 5-MeO-DMT but not typical psychedelics—may indicate recurrent epileptiform activity. The review concludes that further evaluation of 5-MeO-DMT's unique mechanisms is warranted.
Psychedelic Med (New Rochelle)
December 13, 2023
Nicholas A. Carlisle, Haley Maria Dourron, Sarah Maccarthy et al.
12 citations
Chronic shame, often stemming from internalized stigma, disproportionately affects sexual and gender minority (SGM) adults and undermines mental health. This theoretical and philosophical paper argues that psychedelic-assisted therapy holds unique potential to reduce such shame by disrupting rigid self-narratives and fostering self-compassion. The authors suggest that the pharmacological and contextual features of psychedelic experiences—particularly enhanced emotional openness and mystical-type experiences—may directly target shame-related neural and psychological processes. They propose that psychedelic therapy could offer SGM individuals a reparative pathway toward healing and psychological wellness, distinct from conventional treatments. The paper calls for further empirical investigation into psychedelics as a tailored intervention for chronic shame in this population.
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2025
Haley Maria Dourron, Melissa Bradley, Otto Simonsson et al.
7 citations
Greater lifetime psychedelic use was not associated with psychotic symptoms in a cross-sectional survey of 548 adults, even among those with a personal or family history of psychotic or bipolar disorders. In unadjusted analyses, more psychedelic use was linked to less referential thinking, but this association disappeared after adjusting for covariates. A personal history of psychotic disorders was tied to moderately greater magical ideation, referential thinking, and auditory hallucinations, while family history of psychotic disorders related to slightly greater negative symptoms. Notably, among individuals with a personal history of psychotic disorder, auditory hallucinations were less severe as psychedelic use increased, with no such relationship in those without that history. Naturalistic psychedelic use may not heighten psychosis risks.
Journal of Psychoactive Drugs
August 31, 2023
Haley Maria Dourron, Heith Copes, Agasthya Vedre-Kyanam et al.
6 citations
The subjective experiences of diphenhydramine (DPH) misuse, based on 32 first-hand YouTube accounts analyzed with thematic analysis, are predominantly unpleasant, featuring alterations in most sensory modalities, confusion, and dysphoria. Positive effects were rare and often overshadowed by negative aspects. Video makers frequently warned against misuse and occasionally reported adverse post-acute effects. Despite the prevalence of adverse experiences, patterns of repeated misuse were sometimes discussed. Motives for misuse included accessibility, affordability, and legality. The findings suggest DPH misuse can produce substantial, often distressing psychoactive effects that share phenomenological overlap with experiences produced by psychosis.
Front Psychiatry
December 9, 2025
Haley Maria Dourron, Heith Copes, Daniel H. Grossman et al.
3 citations
People diagnosed with non-affective psychotic disorders who used psychedelics reported a mix of positive and negative effects. Common challenges during the acute experience included transient anxiety, sometimes leading to brief hospitalizations. Some participants described psychosis-specific experiences such as reduced self-stigma and insight into their hallucinations and delusions. Perceived long-term benefits varied widely, with some reporting lasting positive changes and others noting negative effects or no lasting impact. The findings suggest psychedelics may pose both risks and potential benefits for this population, highlighting the need for careful safety trials.
November 22, 2024
Haley Maria Dourron, Melissa Bradley, Peter S. Hendricks
1 citation
preprint
Emergency room visits involving hallucinogens are associated with a 21.32 times greater risk of later being diagnosed with a schizophrenia spectrum disorder. The authors discuss implications for developing psychedelics as medicines, but important distinctions are highlighted.
International Journal of Mental Health and Addiction
March 17, 2026
Haley Maria Dourron, Melissa K. Bradley, Heith Copes et al.
Interviews with 19 people diagnosed with non-affective psychotic disorders who had used psychedelics revealed that, while some similarities exist in altered thinking and meaning attribution, most participants reported that psychedelic experiences did not closely resemble their psychosis. Sensory alterations, emotional experience, sense of control, and self-experience were points of contrast. When asked which drug most resembled their psychotic symptoms, the majority endorsed cannabis, followed by dissociative anesthetics and stimulants. The findings suggest that psychedelics may not accurately model many symptoms of psychosis and that interpreting psychedelic experiences as broadly psychosis-like may be misleading.